- Data Presented at the International Congress of Parkinson’s Disease and Movement Disorders - The posters presented from Alterity’s bioMUSE study address the need for incorporating biomarkers as a ...

A team of researchers from NYU Abu Dhabi and the University of Denver has identified a promising small molecule that could ...

Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...

Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced the launch of “Power in the Periphery,” a new disease education campaign for healthcare professionals (HCPs) to raise awareness and deepen ...

(MENAFN- EIN Presswire) Pharma leaders Theravance Biopharma, Ono Pharmaceutical and Ionis Pharmaceuticals are driving a new era of innovation in Multiple System Atrophy care. LAS VEGAS , NV, UNITED ...

Multiple System Atrophy (MSA) is a progressive, rare neurodegenerative disorder adversely affecting the autonomic nervous system, movement, balance, coordination, and various bodily functions.

– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies – MSA is a progressive ...

VALBY, Denmark, March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a ...